Nypta (Zeltia/Noscira) fails Alzheimers Disease study - 13-Oct-2012

Zeltia/ Noscira announces that the primary cognitive endpoint and two of the secondary endpoints were not met in the 26-week ARGO Phase IIb trial involving Nypta (tideglusib). This study evaluated the efficacy of tideglusib versus placebo plus standard of care for the treatment of mild-to-moderate Alzheimers Disease. No decision regarding future development has yet been taken as Zeltia says pending analyses of the other secondary end-points, subpopulations, biomarkers and a magnetic resonance image substudy will be completed in the coming weeks,

Related News

Related Neurological Disorders Information

Related Neurological Disorders Drugs

Back to top

Latest News

10 May 2015
24 May 2013
24 May 2013